StockNews.com Upgrades Emergent BioSolutions (NYSE:EBS) to “Buy”

StockNews.com upgraded shares of Emergent BioSolutions (NYSE:EBS) from a hold rating to a buy rating in a research note published on Tuesday.

A number of other equities analysts have also recently issued reports on EBS. HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of Emergent BioSolutions in a report on Friday, January 10th. Benchmark boosted their price objective on Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a report on Thursday, November 7th.

Emergent BioSolutions Price Performance

EBS opened at $9.37 on Tuesday. The business has a fifty day moving average of $9.36 and a 200 day moving average of $9.17. Emergent BioSolutions has a 52-week low of $1.42 and a 52-week high of $15.10. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30. The stock has a market cap of $507.70 million, a P/E ratio of -2.29 and a beta of 1.60.

Institutional Investors Weigh In On Emergent BioSolutions

A number of institutional investors and hedge funds have recently bought and sold shares of the company. SeaCrest Wealth Management LLC raised its position in Emergent BioSolutions by 3.2% during the 3rd quarter. SeaCrest Wealth Management LLC now owns 118,700 shares of the biopharmaceutical company’s stock valued at $991,000 after purchasing an additional 3,705 shares in the last quarter. Stifel Financial Corp bought a new stake in Emergent BioSolutions during the 3rd quarter valued at $96,000. FORA Capital LLC bought a new stake in Emergent BioSolutions during the 3rd quarter valued at $103,000. Hilltop Holdings Inc. raised its position in shares of Emergent BioSolutions by 7.9% in the 3rd quarter. Hilltop Holdings Inc. now owns 171,266 shares of the biopharmaceutical company’s stock worth $1,430,000 after acquiring an additional 12,515 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC bought a new position in shares of Emergent BioSolutions in the 2nd quarter worth $93,000. 78.40% of the stock is owned by institutional investors.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.